The flow cytometry market is expanding due to increased investment in immuno-oncology and liquid biopsy sectors. With advancements in genome-based research and single-cell analysis, flow cytometry ...
ACS--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer ...
11d
BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global ...
Voice AI company Wispr’s dictation app, Wispr Flow, is seeing great traction. The startup said that, after three months of usage, an average user writes more than 50% of their characters through the ...
Cytek Biosciences has recurring revenue growth, improving margins, and ample cash that should continue compounding shareholder value over time. See why CTKB is a Buy.
Earlier this month, Cytek Biosciences reported third quarter results, posting revenue of US$52.29 million and a net loss of US$5.48 million, as well as reaffirming its full-year 2025 revenue guidance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback